The incidence of gastric cancer is 1.1 M and only 1 in 5 respond to therapy. In addition, gastric cancer causes 770’000 deaths every year. We founded Ymmunobio in September 2021 in Riehen, Switzerland, to address current unmet needs in GI cancers with our lead indication of gastric cancer. Our lead compound (YB-800) is a new and first in class Antibody Drug Conjugate (ADC) candidate that has a vast potential in addressing GI cancer. The new receptor target is present on 50% of the patient’s GI cancers, as compared to other common markers used as ADC targets, which have a much lower prevalence.
Ymmunobio functions as a completely virtual company and has raised CHF 1.32M to date.
Our team consists of very experienced Subject Matter Experts who have been working in the industry for decades.
Ymmunobio functions as a completely virtual company and has raised CHF 1.32M to date.
Our team consists of very experienced Subject Matter Experts who have been working in the industry for decades.